BCEL Atreca, Inc.

21.87-0.19 (-0.86%)
Close: August 23, 2019

21.49-0.38 (-1.74%)
Pre-market

Quote

Previous Close
$21.87
Day Range
$20.96-$23.65
52 Week Range
$10.29-$23.65
Volume
193,557
Avg Volume
86,714
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$611.21M
Enterprise Value (EV)
$711.83M
PE Ratio
-
EV/EBITDA
-19.13
Price/Sales
-
Price/Book
-
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-
EBITDA
-$37.20M
EPS, ttm
-
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
11/27/2019 (94 days)
Debt to Equity
-226%
Debt
$215.12M
Cash
$114.50M
Net Debt
$100.62M

Performance

Beta
-2.40
200 Day Moving Avg
$15.83
50 Day Moving Avg
$15.83
52 Week Change
21.16%
YTD Change
20.30%
1 Month Change
40.82%
3 Month Change
21.16%
6 Month Change
21.16%
1 Year Change
21.16%
2 Year Change
-
5 Year Change
-

Share Count

Shares Outstanding
27.9M
Float
-
Restricted Shares
27.9M
Restricted Shares, %
100.00%

Atreca, Inc. Company Details

Sector: Commercial Services

Industry: Miscellaneous Commercial Services

CEO: John A. Orwin

Website: http://www.atreca.com

Description: Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman in June 11, 2010 and is headquartered in Redwood, CA.

Employees: 85